Oncology Medical Conversation

About Oncology Medical Conversation

Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com

Publisher

COR2ED Medical Education

Category

education · health & fitness · science

Language

en

Explicit

No

First episode

6 Dec 2023

Latest episode

15 Oct 2026

Latest episodes

92 episodes in the feed.

1. 

   15 Oct 2026

   Metastatic TNBC cannot wait

   In this video podcast, Prof. Giuseppe Curigliano and Dr Javier Cortés explore how TROP2-directed antibody–drug conjugates (ADCs) are shaping 1st line treatment for metastatic triple-negative breast cancer (TNBC). Key clinical takeaways: Earlier placement: TROPION-Breast02 and ASCENT-03 support 1st line TROP2 ADC use in defined patients who are not candidates for an ICI; ASCENT-04 supports SG plus pembrolizumab in the studied PD-L1-positive population Individualised selection: Apply each trial to the appropriate patient. Consider disease characteristics, prior therapy, schedule and AE profile; avoid indirect comparisons between Dato-DXd and SG Proactive safety: Translate the Dato-DXd and SG safety evidence into treatment-specific prevention, monitoring and escalation plans before dose 1 You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/breast-cancer-connect/programmes/metastatic-tnbc Or watch on YouTube: https://youtu.be/3gr7g_IeRtU Follow us on social media: LinkedIn: https://www.linkedin.com/company/breastcancerconnect/home/ X: https://x.com/BreastCaConnect Instagram: https://www.instagram.com/cor2edmeded Subscribe to this channel to stay up to date with new medical education programmes as they’re released. This content is intended for healthcare professionals only. This podcast is supported by an Independent Education Grant from AstraZeneca This podcast is developed by cor2ed.com Published on October 2026

2. 

   12 Mar 2026

   Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

   Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer Key clinical takeaways: Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multidisciplinary collaboration. Pathologists are central to this process to ensure accurate interpretation and optimal patient management Incorporating HER2-low and HER2-ultralow categories in biomarker testing is critical for mBC due to the demonstrated efficacy of HER2-targeted antibody-drug conjugates, such as trastuzumab deruxtecan, in these patient subsets, expanding therapeutic options beyond traditional HER2-positive cases High-quality pre-analytical handling and nuanced interpretation are essential for accurate HER2 classification, particularly for HER2-low and –ultralow disease. Small errors in testing or interpretation can lead to missed treatment opportunities. This is the full video. Watch the shorter highlights video here: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=0 Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying one-page snapshot: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=2 Follow us on social media: LinkedIn: https://linkedin.com/company/ntrk-connect X: https://x.com/PresOnc_Connect This content is intended for healthcare professionals only. This video is supported by an Independent Education Grant from Daiichi Sankyo. This video is developed by cor2ed.com Published on March 2026. Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

3. 

   17 Dec 2025

   Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

   Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice. The experts explore: Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template When and why to perform re-biopsy to detect changes in HER2 expression over time Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC. Clinical takeaways DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website Follow us on social media: LinkedIn: https://www.linkedin.com/company/breastcancerconnect/ X: https://x.com/BreastCaConnect This content is intended for healthcare professionals only. This programme is supported by an Independent Education Grant from AstraZeneca. This podcast is developed by cor2ed.com Published December 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Podcast Authority Score: 44 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

77

Social presence

0

YouTube

0

Engagement

27